G1 Therapeutics Partners with Pepper Bio for Lerociclib
Shots:
- G1 Therapeutics & Pepper Bio have entered into a global licensing agreement (except the Asia-Pacific region) for lerociclib, entering into P-II clinical evaluations, covering all indications excl. some radioprotectant applications
- Under the agreement, G1 is entitled to receive a mid-single-digit millions as upfront in 12mos., up to $135M as development & commercial milestones for up to 3 indications plus a double-digit royalty on lerociclib’s total annual net sales
- Furthermore, Pepper Bio obtains exclusive global rights (excl. the Asia-Pacific region) to develop, manufacture & commercialize lerociclib covering all indications excl. some radioprotectant applications whereas license across the Asia-Pacific region has been granted to Genor Biopharma
Ref: G1 Therapeutics | Image: G1 Therapeutics
Related News:- G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
